India’s drug price regulator, the National Pharmaceutical Pricing Authority (NPPA), has issued an office memorandum instructing manufacturers, retailers, dealers, stockists, hospitals, and medical institutions to strictly follow revised maximum retail prices (MRPs) for 137 non-scheduled anti-cancer drugs.
According to the memorandum issued on November 11, the revised prices officially took effect on November 9. The regulatory action follows trade margin cuts aimed at lowering the cost of critical cancer treatments for patients.
Under the order, every retailer, dealer, hospital, and medical institution is required to prominently display the revised price lists at their physical premises as well as on their official websites. Furthermore, hospitals and medical institutions are specifically tasked with monitoring the MRPs of these formulations to ensure full compliance.
The NPPA has also directed State Drug Controllers (SDCs) to closely monitor compliance across manufacturers, dealers, and healthcare facilities. The authority warned that any violations will trigger overcharging proceedings under the provisions of the Drugs (Prices Control) Order (DPCO) of 2013.
To support enforcement, the regulator has provided mechanisms for patients and the public to report issues such as overcharging, drug shortages, or non-availability. Grievances can be submitted via the Pharma Sahi Daam app and portal, through a dedicated helpline at 1800-111-255, or via email to monitoring-nppa@gov.in.
"The strict enforcement of revised pricing for essential medicines like anti-cancer drugs highlights the critical balance between regulatory compliance and affordability in the healthcare sector. For businesses operating in life sciences, healthcare delivery, and pharmaceutical distribution, transparency in pricing and adherence to the Drugs Prices Control Order are paramount. Companies must proactively update their digital platforms and physical outlets to maintain compliance and avoid severe overcharging penalties." — Dr. Shishir Gupta, Founder & CEO, StartupLanes
Recent StartupLanes Articles
Browse through our 30 latest publications on venture capital, startups, and angel investing.